BR112018008577A2 - anticorpos que neutralizam o vírus sincicial respiratório humano - Google Patents
anticorpos que neutralizam o vírus sincicial respiratório humanoInfo
- Publication number
- BR112018008577A2 BR112018008577A2 BR112018008577A BR112018008577A BR112018008577A2 BR 112018008577 A2 BR112018008577 A2 BR 112018008577A2 BR 112018008577 A BR112018008577 A BR 112018008577A BR 112018008577 A BR112018008577 A BR 112018008577A BR 112018008577 A2 BR112018008577 A2 BR 112018008577A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- respiratory syncytial
- syncytial virus
- human respiratory
- neutralize human
- Prior art date
Links
- 241000711920 Human orthopneumovirus Species 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
a presente invenção refere-se a anticorpos monoclonais que têm altos níveis neutralizantes anti-rsv. a invenção fornece adicionalmente ácidos nucleicos isolados que codificam os anticorpos da invenção e células hospedeiras transformadas com os mesmos. a invenção ainda fornece adicionalmente métodos diagnósticos, profiláticos e terapêuticos empregando os anticorpos e ácidos nucleicos da invenção, particularmente como um agente de imunoterapia passiva em crianças e idosos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562247841P | 2015-10-29 | 2015-10-29 | |
US201662367359P | 2016-07-27 | 2016-07-27 | |
PCT/US2016/058975 WO2017075124A1 (en) | 2015-10-29 | 2016-10-27 | Antibody neutralizing human respiratory syncytial virus |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112018008577A2 true BR112018008577A2 (pt) | 2018-10-30 |
BR112018008577A8 BR112018008577A8 (pt) | 2023-02-07 |
Family
ID=57227165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018008577A BR112018008577A8 (pt) | 2015-10-29 | 2016-10-27 | Anticorpos que neutralizam o vírus sincicial respiratório humano |
Country Status (27)
Country | Link |
---|---|
US (7) | US9963500B2 (pt) |
EP (1) | EP3368562A1 (pt) |
JP (1) | JP6880014B2 (pt) |
KR (1) | KR102140113B1 (pt) |
CN (1) | CN108431036B (pt) |
AU (3) | AU2016344070B2 (pt) |
BR (1) | BR112018008577A8 (pt) |
CA (1) | CA3001878C (pt) |
CL (1) | CL2018001141A1 (pt) |
CO (1) | CO2018004321A2 (pt) |
GE (1) | GEP20217260B (pt) |
HK (1) | HK1254950A1 (pt) |
IL (1) | IL258743B2 (pt) |
JO (2) | JO3555B1 (pt) |
MA (1) | MA43108A (pt) |
MX (1) | MX2018005047A (pt) |
MY (1) | MY192714A (pt) |
NI (1) | NI201800052A (pt) |
PE (1) | PE20181270A1 (pt) |
PH (1) | PH12018500916A1 (pt) |
SG (2) | SG10201809694PA (pt) |
SV (1) | SV2018005678A (pt) |
TN (1) | TN2018000134A1 (pt) |
TW (1) | TWI743057B (pt) |
UA (1) | UA127516C2 (pt) |
WO (1) | WO2017075124A1 (pt) |
ZA (1) | ZA201802369B (pt) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
TWI761453B (zh) | 2017-03-01 | 2022-04-21 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
RU2019138507A (ru) | 2017-05-02 | 2021-06-02 | Мерк Шарп И Доум Корп. | Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1 |
EP3695003A4 (en) * | 2017-10-13 | 2021-12-22 | Adimab, LLC | ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS AND METHOD OF GENERATING AND USING THEREOF |
CA3088546A1 (en) | 2018-01-29 | 2019-08-01 | Merck Sharp & Dohme Corp. | Stabilized rsv f proteins and uses thereof |
BR112020015588A2 (pt) * | 2018-01-31 | 2021-01-05 | The Wistar Institute Of Anatomy And Biology | Molécula de ácido nucleico codificando um ou mais anticorpos sintéticos, composição, anticorpo monoclonal anti-rsv, método para prevenir ou tratar uma doença, e, formulação. |
WO2019165019A1 (en) * | 2018-02-21 | 2019-08-29 | Vanderbilt University | Antibodies to human respiratory syncytial virus protein f pre-fusion conformation and methods of use therefor |
JP2021534239A (ja) * | 2018-08-08 | 2021-12-09 | トレリス・バイオサイエンス,エルエルシー | Rsvの改善された受動的および能動的ワクチン |
MX2021004356A (es) * | 2018-10-18 | 2021-05-31 | Merck Sharp & Dohme Llc | Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas. |
CN110016079B (zh) * | 2018-12-18 | 2019-12-24 | 珠海泰诺麦博生物技术有限公司 | 抗呼吸道合胞病毒的中和抗体及其应用 |
CN111606993B (zh) * | 2019-02-26 | 2022-06-28 | 中国科学院上海生命科学研究院 | 抗呼吸道合胞病毒的全人广谱中和抗体4f1及其应用 |
KR102467943B1 (ko) * | 2020-06-25 | 2022-11-16 | 재단법인 목암생명과학연구소 | 항-rsv 항체 및 이를 포함하는 약학적 조성물 |
AU2021399453A1 (en) * | 2020-12-18 | 2023-07-27 | Zhuhai Trinomab Pharmaceutical Co., Ltd. | Respiratory syncytial virus-specific binding molecule |
WO2022268120A1 (en) * | 2021-06-22 | 2022-12-29 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-rsv antibodies and uses thereof |
WO2023025253A1 (zh) * | 2021-08-25 | 2023-03-02 | 甘李药业股份有限公司 | 抗rsv病毒抗体及其应用 |
CA3235979A1 (en) * | 2021-12-06 | 2023-06-15 | Xiamen University | Antibody for recognizing rsv pre-f protein and use thereof |
CN116987183A (zh) * | 2022-07-22 | 2023-11-03 | 北京智仁美博生物科技有限公司 | 抗呼吸道合胞病毒中和性抗体及其用途 |
WO2024067151A1 (zh) * | 2022-09-27 | 2024-04-04 | 深圳重链生物科技有限公司 | 抗呼吸道合胞病毒抗体及其相关应用 |
WO2024120517A1 (zh) * | 2022-12-08 | 2024-06-13 | 南京诺唯赞生物科技股份有限公司 | 特异性结合rsv的抗体 |
CN117720650A (zh) * | 2024-02-04 | 2024-03-19 | 北京百普赛斯生物科技股份有限公司 | 抗人呼吸道合胞病毒抗体及其应用 |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
WO1986005807A1 (en) | 1985-04-01 | 1986-10-09 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2 Inc | Geänderte antikörper. |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
CA2006596C (en) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | Chemically-modified g-csf |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
GB9019812D0 (en) | 1990-09-11 | 1990-10-24 | Scotgen Ltd | Novel antibodies for treatment and prevention of infection in animals and man |
EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
US5824307A (en) | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US6129914A (en) | 1992-03-27 | 2000-10-10 | Protein Design Labs, Inc. | Bispecific antibody effective to treat B-cell lymphoma and cell line |
GB9207479D0 (en) | 1992-04-06 | 1992-05-20 | Scotgen Ltd | Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US6685942B1 (en) | 1993-12-10 | 2004-02-03 | The Scripps Research Institute | Human neutralizing monoclonal antibodies to respiratory syncytial virus |
EP0671927B1 (en) | 1992-09-16 | 2003-01-15 | The Scripps Research Institute | Human neutralizing monoclonal antibodies to respiratory syncytial virus |
CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
US5532210A (en) | 1994-06-08 | 1996-07-02 | E. I. Du Pont De Nemours And Company | High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5811524A (en) | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
AU7240096A (en) | 1995-09-18 | 1997-04-09 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Neutralizing monoclonal antibodies to respiratory syncytial virus |
CA2270288A1 (en) | 1996-11-01 | 1998-05-14 | Smithkline Beecham Corporation | Human monoclonal antibodies |
US20020141990A1 (en) | 1996-11-01 | 2002-10-03 | Smithkline Beecham Corporation | Anti-RSV human monoclonal antibodies |
US5842307A (en) | 1996-11-15 | 1998-12-01 | May; Kenzel | Self-adjusting, automatic spot weed sprayer |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
EP1724282B1 (en) | 1997-05-21 | 2013-05-15 | Merck Patent GmbH | Method for the production of non-immunogenic proteins |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
GB9818110D0 (en) | 1998-08-19 | 1998-10-14 | Weston Medical Ltd | Needleless injectors and other devices |
US6096002A (en) | 1998-11-18 | 2000-08-01 | Bioject, Inc. | NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method |
KR101077001B1 (ko) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
PT1176195E (pt) | 1999-04-09 | 2013-07-18 | Kyowa Hakko Kirin Co Ltd | Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico |
CO5280147A1 (es) | 1999-05-18 | 2003-05-30 | Smithkline Beecham Corp | Anticuerpo humano monoclonal |
AU7950400A (en) | 1999-10-19 | 2001-04-30 | Kyowa Hakko Kogyo Co. Ltd. | Process for producing polypeptide |
US20050175986A1 (en) | 2000-05-09 | 2005-08-11 | Smit Kline Beecham Corporation | Human monoclonal antibody |
US7449308B2 (en) | 2000-06-28 | 2008-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
PT1522590E (pt) | 2000-06-28 | 2009-10-26 | Glycofi Inc | Métodos para a produção de glicoproteínas modificadas |
US6374470B1 (en) | 2000-10-06 | 2002-04-23 | Milliken & Company | Face plate for spun-like textured yarn |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US6818216B2 (en) | 2000-11-28 | 2004-11-16 | Medimmune, Inc. | Anti-RSV antibodies |
MXPA04001072A (es) | 2001-08-03 | 2005-02-17 | Glycart Biotechnology Ag | Variantes de glicosilacion de anticuerpos que tienen citotoxicidad celulares dependiente de anticuerpos incrementada. |
WO2003086310A2 (en) | 2002-04-12 | 2003-10-23 | Ramot At Tel Aviv University Ltd. | Prevention of brain inflammation as a result of induced autoimmune response |
GB2398783A (en) | 2003-02-26 | 2004-09-01 | Antonio Lanzavecchia | A method for producing immortalised human B memory lymphocytes |
US7410483B2 (en) | 2003-05-23 | 2008-08-12 | Novare Surgical Systems, Inc. | Hand-actuated device for remote manipulation of a grasping tool |
WO2005120571A2 (en) | 2004-06-07 | 2005-12-22 | Ramot At Tel Aviv University Ltd. | Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation |
AU2005269759A1 (en) | 2004-07-21 | 2006-02-09 | Glycofi, Inc. | Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform |
SG190665A1 (en) | 2004-07-30 | 2013-06-28 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and methods using same |
TW200636064A (en) * | 2004-10-28 | 2006-10-16 | Centocor Inc | Anti-respiratory syncytial virus antibodies, antigens and uses thereof |
WO2006050166A2 (en) | 2004-10-29 | 2006-05-11 | Medimmune, Inc. | Methods of preventing and treating rsv infections and related conditions |
WO2006110214A2 (en) | 2005-04-08 | 2006-10-19 | Medimmune, Inc. | Antibodies against mammalian metapneumovirus |
EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
RS53072B (en) | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | HUMAN RECEPTOR ANTIBODIES PROGRAMMED DEATH PD-1 |
EP2201040A1 (en) | 2007-09-24 | 2010-06-30 | Vanderbilt University | Monoclonal antibodies to respiratory syncytial virus and uses thereof |
US20090258013A1 (en) | 2008-04-09 | 2009-10-15 | Genentech, Inc. | Novel compositions and methods for the treatment of immune related diseases |
EA023179B1 (ru) | 2009-08-13 | 2016-05-31 | Круселл Холланд Б.В. | Антитела против респираторного синцитиального вируса (pcb) и способы их применения |
AU2009353693B2 (en) | 2009-10-06 | 2016-07-21 | Medimmune Ltd | RSV-specific binding molecule |
US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
KR101896124B1 (ko) | 2010-07-09 | 2018-09-07 | 얀센 백신스 앤드 프리벤션 비.브이. | 항-인간 호흡기 세포융합 바이러스(rsv) 항체 및 사용 방법 |
US20140141037A1 (en) | 2012-11-20 | 2014-05-22 | Novartis Ag | Rsv f prefusion trimers |
KR20150085843A (ko) | 2012-11-20 | 2015-07-24 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | Rsv f 융합전 삼합체 |
AU2013355379B2 (en) | 2012-12-04 | 2018-08-09 | Oncomed Pharmaceuticals, Inc. | Immunotherapy with binding agents |
JP6450688B2 (ja) | 2013-02-01 | 2019-01-09 | メディミューン,エルエルシー | 呼吸器合胞体ウイルスfタンパク質エピトープ |
TWI659968B (zh) | 2013-03-14 | 2019-05-21 | 再生元醫藥公司 | 針對呼吸道融合病毒f蛋白質的人類抗體及其使用方法 |
-
2016
- 2016-10-20 JO JOP/2016/0224A patent/JO3555B1/ar active
- 2016-10-27 US US15/335,560 patent/US9963500B2/en active Active
- 2016-10-27 SG SG10201809694PA patent/SG10201809694PA/en unknown
- 2016-10-27 GE GEAP201614794A patent/GEP20217260B/en unknown
- 2016-10-27 CN CN201680077215.0A patent/CN108431036B/zh active Active
- 2016-10-27 SG SG11201803524UA patent/SG11201803524UA/en unknown
- 2016-10-27 MX MX2018005047A patent/MX2018005047A/es unknown
- 2016-10-27 WO PCT/US2016/058975 patent/WO2017075124A1/en active Application Filing
- 2016-10-27 BR BR112018008577A patent/BR112018008577A8/pt active Search and Examination
- 2016-10-27 TN TNP/2018/000134A patent/TN2018000134A1/en unknown
- 2016-10-27 MA MA043108A patent/MA43108A/fr unknown
- 2016-10-27 JP JP2018521052A patent/JP6880014B2/ja active Active
- 2016-10-27 KR KR1020187014639A patent/KR102140113B1/ko active IP Right Grant
- 2016-10-27 UA UAA201805841A patent/UA127516C2/uk unknown
- 2016-10-27 AU AU2016344070A patent/AU2016344070B2/en active Active
- 2016-10-27 MY MYPI2018000595A patent/MY192714A/en unknown
- 2016-10-27 PE PE2018000607A patent/PE20181270A1/es unknown
- 2016-10-27 EP EP16790858.1A patent/EP3368562A1/en active Pending
- 2016-10-27 IL IL258743A patent/IL258743B2/en unknown
- 2016-10-27 TW TW105134803A patent/TWI743057B/zh active
- 2016-10-27 CA CA3001878A patent/CA3001878C/en active Active
-
2018
- 2018-03-22 US US15/928,503 patent/US10323079B2/en active Active
- 2018-03-22 US US15/928,566 patent/US10072072B2/en active Active
- 2018-03-22 US US15/928,438 patent/US10358480B2/en active Active
- 2018-04-11 ZA ZA2018/02369A patent/ZA201802369B/en unknown
- 2018-04-24 CO CONC2018/0004321A patent/CO2018004321A2/es unknown
- 2018-04-25 NI NI201800052A patent/NI201800052A/es unknown
- 2018-04-27 PH PH12018500916A patent/PH12018500916A1/en unknown
- 2018-04-27 SV SV2018005678A patent/SV2018005678A/es unknown
- 2018-04-27 CL CL2018001141A patent/CL2018001141A1/es unknown
- 2018-11-02 HK HK18114054.4A patent/HK1254950A1/zh unknown
-
2019
- 2019-06-07 US US16/434,729 patent/US11008380B2/en active Active
-
2020
- 2020-01-31 AU AU2020200729A patent/AU2020200729A1/en not_active Abandoned
- 2020-05-03 JO JOP/2020/0091A patent/JOP20200091A1/ar unknown
- 2020-12-08 US US17/115,510 patent/US11566065B2/en active Active
-
2022
- 2022-04-13 AU AU2022202475A patent/AU2022202475A1/en active Pending
- 2022-12-13 US US18/065,172 patent/US11981726B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018008577A2 (pt) | anticorpos que neutralizam o vírus sincicial respiratório humano | |
JOP20200192A1 (ar) | أجسام مضادة لـ tigit | |
MX2021007679A (es) | Anticuerpos humanos para hemaglutinina de influenza. | |
BR112016015140A2 (pt) | imunoglobulina com fabs in-tandem e usos das mesmas | |
MX2022007522A (es) | Anticuerpos anti-cd27. | |
BR112016013109A2 (pt) | anticorpos de anti-siglec-8 e métodos de seu uso | |
UY36905A (es) | Anticuerpos neutralizantes de poliomavirus | |
BR112014026740A8 (pt) | anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo | |
BR112016019176A2 (pt) | anticorpos il-21 | |
BR112016006210A2 (pt) | terapia e vacina contra gripe | |
MY189495A (en) | Hand, foot, and mouth vaccines and methods of manufacture and use thereof | |
AR100944A1 (es) | ANTICUERPOS ANTAGONISTAS DE INTERFERÓN a Y w | |
MX2017005687A (es) | Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia. | |
EA201792282A1 (ru) | Способы лечения заболеваний | |
ECSP18039827A (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
EA201891048A1 (ru) | Антитело, нейтрализующее респираторно-синцитиальный вирус человека | |
AR095869A1 (es) | Anticuerpos humanos que se unen a la proteína g del rsv | |
AR095870A1 (es) | Anticuerpos humanos que se unen a la proteína g del rsv | |
TH1501005414A (th) | แอนติบอดีของมนุษย์ต่อเรสไพราทอรีซินไซเทียลไวรัส f โปรตีน และวิธีการใช้ของมัน |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: MERCK SHARP AND DOHME LLC (US) |